Sunshine Biopharma (SBFM)
Commercializer of Canadian generic medicines with early-stage oncology and antiviral research.
Something off on this page? Send us feedback.
Sells Canadian generic prescription drugs through Nora Pharma across pharmacy channels under licensed and distribution arrangements. A smaller proprietary pipeline targets liver cancer and SARS-coronavirus infections, while commercial operations depend on Health Canada approvals, provincial drug policies, and third-party suppliers.
Commercializes generic prescription drugs in Canada through Nora Pharma, using in-licensed, cross-licensed, and distribution arrangements. Products cover oncology, cardiovascular medicine, central-nervous-system disorders, anti-infectives, urology, diabetes, allergy, and women's health, and reach pharmacies, distributors, wholesalers, and direct pharmacy customers. Quebec is the principal market, with smaller exposure to Ontario, Alberta, and British Columbia.
Maintains smaller proprietary research programs: K1.1, an mRNA-lipid-nanoparticle liver-cancer candidate, and SBFM-PL4, a small-molecule protease inhibitor for SARS-coronavirus infections. Both remain at animal testing and had no regulatory filings as of the annual report. Canadian sales depend on Health Canada approvals, provincial pricing and formularies, and overseas suppliers that manufacture nearly all Nora products.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.7M · Total debt $678.3K · Total assets $33.6M · Shareholders' equity $27.5M
- Revenue
- $9.3M
- Operating income
- −$1.6M
- Net income
- −$1.6M
No dividends on record.
| Insiders | 2.87% | 68.3K shares | |
|---|---|---|---|
| 2 holders · as of Aug 11, 2026 | |||
| Strategic holders | 8.41% | 200.0K shares | |
| 1 holder · as of Jul 8, 2026 | |||
| Other | 88.72% | 2.11M shares | |
| remainder | |||
2.38M company shares as of Sep 17, 2026 · holders as of their latest filing
Two share counts disagree (3.88M in the company's Sep 23, 2026 report, 2.38M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Alta Partners LLCStrategic | 8.41% | 200,000 | filed Jul 8, 2026 |
David NatanInsiderdirector | 2.87% | 68,300 | filed Aug 11, 2026 |
Michel RoyInsiderofficer: Chief Commercial Officer | 0.00% | 0 | filed Jan 21, 2025 |
ApplicableInsider | —16.40% of class, as filed | — | filed Nov 2, 2022 |
L1 Capital Global Opportunities Master Fund, Ltd.Institution | —5.83% of class, as filed | — | filed May 22, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Teva (ADR)
Large Canadian generic and biosimilar portfolio contests pharmacy access.
- Viatris
Broad Canadian generics compete across major prescription therapies.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sunshine Biopharma | $0.9097 | +0.38% | $2.2M | — | — | 0.1 | −1.2% |
| Teva (ADR) | $39.60 | +0.20% | $46.03B | 65.9 | 14.1 | 2.7 | −0.8% |
| Viatris | $17.41 | +1.34% | $20.01B | — | 6.8 | 1.4 | +4.9% |
| Median | 65.9 | 10.5 | 2.0 | +2.0% |